Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Depreciation and Depletion (2016 - 2023)

Historic Depreciation and Depletion for Tg Therapeutics (TGTX) over the last 8 years, with Q3 2023 value amounting to $73000.0.

  • Tg Therapeutics' Depreciation and Depletion fell 394.74% to $73000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $246000.0, marking a year-over-year decrease of 2064.52%. This contributed to the annual value of $303000.0 for FY2022, which is 744.68% up from last year.
  • As of Q3 2023, Tg Therapeutics' Depreciation and Depletion stood at $73000.0, which was down 394.74% from $32000.0 recorded in Q2 2023.
  • In the past 5 years, Tg Therapeutics' Depreciation and Depletion ranged from a high of $80000.0 in Q4 2021 and a low of $23000.0 during Q1 2019
  • For the 5-year period, Tg Therapeutics' Depreciation and Depletion averaged around $53473.7, with its median value being $59000.0 (2021).
  • In the last 5 years, Tg Therapeutics' Depreciation and Depletion skyrocketed by 9705.88% in 2021 and then plummeted by 5897.44% in 2023.
  • Quarter analysis of 5 years shows Tg Therapeutics' Depreciation and Depletion stood at $28000.0 in 2019, then surged by 89.29% to $53000.0 in 2020, then soared by 50.94% to $80000.0 in 2021, then dropped by 8.75% to $73000.0 in 2022, then changed by 0.0% to $73000.0 in 2023.
  • Its Depreciation and Depletion was $73000.0 in Q3 2023, compared to $32000.0 in Q2 2023 and $68000.0 in Q1 2023.